Alexa Start Cardio Medica

CardioMedica is an education and information channel using the AudioScholar platform (created by AudioEducate) for the InternationalAtherosclerosis Society(IAS). The program is offered in English on Amazon Alexa and can be accessed on any device featuring Amazon Alexa or the Alexa App. (Coming soon to Google Home ). These presentations are based on the same education videos offered in the IAS Education Center.

BATTLE BRAZIL - Video Series v6

NAFLD/NASH: The Cardiometabolic Connection

The prevalence of non-alcoholic fatty liver disease (NAFLD), is the main hepatic complication of postprandial dysmetabolism, obesity, type 2 diabetes mellitus (T2DM), and the metabolic syndrome. Its emergence has risen dramatically since 1980, when it was a perplexing and sporadically observed disease to a current estimated 25% global prevalence.

Its strongest risk factors are like those of ASCVD. Issues currently arise with diagnosis, lack of treatment options and the multifactorial nature of the disease. The challenge for clinicians, payers and public health officials grappling with the condition is thus to identify who among those with NAFLD have greater chance of liver disease progression, development of ASCVD and therefore are at greatest necessity to treat.

This program presented by the International Atherosclerosis Society (IAS) was funded by educational support from Pfizer Pharmaceuticals. Detailed information on the faculty, disclosures, and additional available references or to tke this program online, visit the IAS Education Center.


N1Segment 1- The Background of the ConnectionNASH6/27/22
N2Segment 2- Patient Identification and Risk StratificationNASH6/27/22
N3Segment 3- Combined Patient ManagementNASH6/27/22
N4Segment 4- Final MessagesNASH6/27/22




The IAS has developed the worldwide effort aimed at health care professionals to comprehensively address the matter of LDL-C attributable risk in the prevention of Major Adverse Cardiology Events (MACE) and mortality  This will be accomplished through a series of nine (9) videos presented by some of the most recognizable and prominent leaders in cardiology and lipid medicine from across the globe. 

Importantly, the videos will emphasize the translation of current guidelines and evidence into practice approaches that heighten both clinical and patient success.  Every video, based on real-world issues and evidence, will focus on implementing practical physician and patient strategies. 


LDL1Evidance of LDL-C as a cause of Atheroscierotic Cardiovascular DiseaseLipids9/27/21
LDL2The Sad and Inadequate Reality of Cholesterol Control WorldwideLipids9/27/21
LDL3For A S C V D Prevention, the Lower the LDL-C the BetterLipids9/27/21
LDL4Safety of Intensive LDL-C ReductionLipids9/27/21
LDL5Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic LipoproteinsLipids9/27/21
LDL6 Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost EffectivenessLipids9/27/21
LDL7Efficacy, Feasibility, and Safety of Early Use of Monoclonal PCSK9 Inhibitors after an Acute Coronary SyndromeLipids9/27/21
LDL8 Use of PCSK9 Inhibitors in Familial Hypercholesterolemia PatientsLipids9/27/21
LDL9 Future Therapies for Dyslipidemia TreatmentLipids9/27/21


Preventing Atherosclerotic Cardiovascular Disease in Patients with Diabetes Mellitus

The IAS recognizes that system-level improvements are needed in the prevention of ASCVD in patients with diabetes and that progress in CVD risk factor control is slowing. Based on US data, only 14% of patients meet targets for all A1C, BP, lipids, and nonsmoking status. 33-49% of patients still do not meet one or several targets for A1C, blood pressure, or lipids. This problem is exacerbated globally as even fewer meet these targets in many low-and middle-income countries.

The purpose of this video series are to provide a better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focused discussion on statins and newer diabetes drugs. Each section is introducted by general lecture of the clinical prevalence and evidence. The panel will discuss the real world implications and provide practical implemtation advice.


Catalog Title Keyword Date
D1 Natural History and ASCVD Risk Stratification in Type 2 Diabetes Diabetes 1/1/2020
D2 Statins, LDL-C Lowering, and Prevention of ASCVD in Diabetes Mellitus Diabetes 1/1/2020
D3 Safety of Statin Therapy in Type 2 Diabetes Mellitus Diabetes 1/1/2020
D4 Managing Symptoms During Statin Therapy Diabetes 1/1/2020
D5 Residual Dyslipidemia in Type 2 Diabetes Mellitus and Implications for ASCVD Prevention Diabetes 1/1/2020
D6 The Role of Newer Type 2 Diabetes Mellitus Drugs for ASCVD Prevention Diabetes 1/1/2020
D7 Putting It All Together Diabetes 1/1/2020

Using your Amazon Alexa

First time users: Enable the Skill by saying “Alexa Enable Cardio Medica“
Established users: Say , “Alexa Start Cardio Medica“

Alexa Says” Welcome, if you would like to start a program say Begin”

OPTION 1: Just say BEGIN

Alexa will play the most recent program uploaded.  

When done you can continue in date order to other programs sorted by release date.

OPTION 2: To play a specific  program by Keyword.*


You can find the program keyword in the program drop down menu.   

OPTION 3: You want a specific module within a program, then use a “Catalog Number”


You can find the program catalog number in the program drop down menu.   

Frequently Asked

What to do if you don’t have an Alexa device.

You can download the app for your computer or mobile phone.

Windows– Download the Alexa app in the Microsoft Store
Android- The Alexa app can be found in the Google Play Store
Apple- The Alexa app can be found in the App Store

Audio or Video (both work)

All programs are created for Audio and Video playback. If you have a device without a screen or are streaming by bluetooth, you can still listen to the audio presentations.

Country and Language Support

All programs are created in English and avaialble in countries that provide Alexa services in English only. 

Standard Alexa Responses in Cardio Medica

Alexa listens for standard phrases that allow it to be interactive and Cardio Medica uses standard Alexa commands.


At key points in the program Alexa will prompt you for the desired response. Like please say “yes or no“,” true or false” or to give a short answer to a multiple-choice question like “A”, “B”.


Note: If you are in place with background noise, Alexa may not understand what you are saying, she will ask again or exit the skill when given a confusing answer.

Additional Commands to use with CardioMedica

· Alexa Start Cardio Medica—Starts the skill

· Alexa Begin– Starts the requested program

· Alexa Stop or Alexa Pause – Pauses the audio

· Alexa Play or Resume– Resumes the Audio

·Alexa Cancel– Ends Cardio Medica

· Alexa Forward “XXX” seconds(or minutes)- Jumps forward in the Audio

·Alexa Back “XXX” seconds(or minutes)- Jumps back in case you missed something.

·Alexa Next- When the audio or video portion is finished use this command to move forward.


Please email us using the contact form and describe your issue which can help improve this technology.